Wilms tumor gene 1 expression: An independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 47, Issue 4, 2012, Pages 499-507

  Zhao, X S ^a   Jin, S ^a   Zhu, H H ^a   Xu, L P ^a   Liu, D H ^a   Chen, H ^a   Liu, K Y ^a   Huang, X J ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

acute leukemia; allogeneic hematopoietic SCT; minimal residual diseases; relapse; Wilms' tumor gene 1

Indexed keywords

MOLECULAR MARKER;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT INFORMATION; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WILM TUMOR GENE 1;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; WT1 PROTEINS;

EID: 84859464436     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.121     Document Type: Article

References (26)

1. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079. (Pubitemid 24328100)
2. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994; 8: 2138-2143.
3. Ogawa H, Ikegame K, Kawakami M, Tamaki H. WT1 gene transcript assay for relapse in acute leukemia after transplantation. Leuk Lymphoma 2004; 45: 1747-1753. (Pubitemid 38997140)
4. Gianfaldoni G, Mannelli F, Ponziani V, Longo G, Bencini S, Bosi A et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica 2010; 95: 833-836.
5. Hamalainen MM, Kairisto V, Juvonen V, Johansson J, Auren J, Kohonen K et al. Wilms tumour gene 1 over-expression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol 2008; 80: 201-207. (Pubitemid 351253460)
6. Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009; 33: 384-390.
7. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006; 24: 1507-1515. (Pubitemid 46638771)
8. Uzunel M, Ringden O. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 47-52. (Pubitemid 38159703)
9. Imashuku S, Terui K, Matsuyama T, Asami K, Tsuchiya S, Ishii E et al. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan. Bone Marrow Transplant 2003; 31: 1127-1135. (Pubitemid 36857370)
10. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698-1704. (Pubitemid 36237562)
11. Candoni A, Toffoletti E, Gallina R, Simeone E, Chiozzotto M, Volpetti S et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant 2011; 25: 308-316.
12. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357. (Pubitemid 38072573)
13. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 2003; 17: 2474-2486. (Pubitemid 38072587)
14. Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 2003; 78: 349-356. (Pubitemid 37532392)
15. Qin YZ, Liu YR, Zhu HH, Li JL, Ruan GR, Zhang Y et al. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 2008; 30: 317-323.
16. Simpson E, Matsunaga T. Physiological function of major histocompatibility complex macromolecules. Facts and hypotheses. Transplantation 1979; 27: 295-297. (Pubitemid 9167076)
17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217. (Pubitemid 10036817)
18. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
19. Huang XJ, Liu DH, Liu KY, Xu LP, Chen YH, Wang Y et al. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008; 28: 276-283.
20. Candoni A, Tiribelli M, Toffoletti E, Cilloni D, Chiarvesio A, Michelutti A et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009; 82: 61-68.
21. Busse A, Gokbuget N, Siehl JM, Hoelzer D, Schwartz S, Rietz A et al. Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann Hematol 2009; 88: 1199-1205.
22. Gu WY, Chen ZX, Hu SY, Zhu J, Wang ZL, Yan F et al. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation]. Zhonghua yi xue za zhi 2005; 85: 444-447. (Pubitemid 40340401)
23. Lasa A, Carricondo M, Estivill C, Bussaglia E, Gich I, Brunet S et al. WT1 monitoring in core binding factor AML: comparison with specific chimeric products. Leuk Res 2009; 33: 1643-1649.
24. Lin F, van Rhee F, Goldman JM, Cross NC. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87: 4473-4478. (Pubitemid 26152290)
25. Jacobsohn DA, Tse WT, Chaleff S, Rademaker A, Duerst R, Olszewski M et al. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haemat 2009; 146: 669-674.
26. Jin S, Liu DH, Xu LP, Chen H, Chen YH, Qin YZ et al. [The significance of dynamic detection of WT1 expression on patients of hematologic malignancy following allogeneic hematopoietic stem cell transplantation]. Zhonghua nei ke za zhi [Chin J Intern Med] 2008; 47: 578-581.